Clinical Outcomes with MiniMed TM 780G Advanced Hybrid Closed-Loop Therapy in 2- to 6-Year-Old Children with Type 1 Diabetes
Authors' conclusion
AHCL is a feasible option for management of young children with type 1 diabetes.
Study context
- Population
- Children aged 2–7 years with T1D on insulin pump therapy; mean (SD) age 5.3 (0.8) years10 completed
- Participants
- 11 children
- Outcome
- Continuous glucose monitoring (CGM) metrics
Methodological detailssingle-group, 2-week manual mode phase followed by 6-week advanced hybrid closed-loop (AHCL) phase
- Single-group
- 2-week manual mode phase followed by 6-week AHCL phase
Main finding
As reported in the abstract
CGM metrics in AHCL
Time in closed loop
96.7 (3.9)%
TIR, mean (SD)
72.6 (7.4)%
Time <70 mg/dL
3.0 (1.74)%
Time <54 mg/dL
0.63 (0.46)%
Original publication
Clinical Outcomes with MiniMed TM 780G Advanced Hybrid Closed-Loop Therapy in 2- to 6-Year-Old Children with Type 1 Diabetes. Diabetes Technol Ther. Published 8 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →